Sensitivity and specificity of prostate health index (PHI), for the scrutiny of prostate cancer, avoiding the practice of unnecessary biopsies
DOI:
https://doi.org/10.48193/xyr93b25Keywords:
Diagnosis, prostate cancer, prostate specific antigen, prostate health indexAbstract
Objective: To determine the sensitivity and specificity of the prostate health index (PHI) for prostate cancer screening in Mexican population with total prostate antigen (PSA) levels greater than 4ng/mL, in a second level hospital.
Method: An exploratory, cross-sectional, retrospective, diagnostic test-type study was performed in a second level hospital. Data were collected from 84 patients who underwent prostate biopsy, selected through the review of laboratory studies. The sensitivity, specificity, positive and negative predictive values, ROC curve and the area under the curve (AUC) were measured.
Results: The sensitivity and specificity of the PHI obtained was 82 % and 84 % respectively. We considered 43 points as the optimal cutoff given by the ROC curve, with an area under the curve of 0.930; likewise, the positive predictive value was 72 % and the negative predictive value was 90%.
Limitations: The main limitation is the sample size.
Originality: It is necessary the application of new biomarkers as a screening method with a greater reliability for the diagnosis of prostate cancer to avoid the unnecessary practice of biopsies in Mexican population.
Conclusions: The study demonstrated a good prostate health index (PHI) sensitivity and specificity.
References
Leslie SW, Soon-Sutton TL, R I A, Sajjad H, Skelton WP. Prostate Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Islas Pérez LÁ, Martínez Reséndiz JI, Ruiz Hernández A, Ruvalcaba Ledezma JC, Benítez Medina A, Beltran Rodríguez MG, et al. Epidemiología del cáncer de próstata, sus determinantes y prevención. Journal of Negative and No Positive Results. 2020;5(9): 1010–1022. https://dx.doi.org/10.19230/jonnpr.3686.
Castillejos-Molina RA, Gabilondo-Navarro FB, Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Pública de México. 2016;58(2): 279–284. https://doi.org/10.21149/spm.v58i2.7797
Jara Rascón J, Subirá Ríos D, LLedó García E, Martínez Salamanca JI, Moncada Iribarren I, Hernández Fernández C. Evaluación del antígeno especifico prostático (PSA) ajustado al volumen de la zona transicional en la detección del cáncer de próstata. Actas Urológicas Españolas. 2005;29(5): 485–492.
Morejón WV, Sena BJ, Vega YP, Águila Y de la CR, García IC. Antígeno prostático específico como predictor del diagnóstico de adenocarcinoma prostático. Revista Finlay. 2015;5(4): 221–227.
Gelpi-Méndez JA, Gómez-Fernández E, Martín-Barallat J, Cortés-Arcas MV, Monsonis-Artero JV, Calvo-Mora A. Valores de referencia del antígeno prostático específico (PSA) en 63.926 trabajadores sin síntomas prostáticos que participaron en el cribado de cáncer de próstata desarrollado por la Sociedad de Prevención de Ibermutuamur durante el año 2006. Actas Urológicas Españolas. 2010;34(8): 669–676.
Ferro M, De Cobelli O, Lucarelli G, Porreca A, Busetto GM, Cantiello F, et al. Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences. 2020;21(4): 1184. https://doi.org/10.3390/ijms21041184.
Zegarra-Montes L, Sarria-Bardales G, Martínez-Perez D, Del-Castillo-Pacora R, Dyer-Velarde-Álvarez R, Trelles-De-Belaunde M. Viabilidad y seguridad de la biopsia prostática transperineal en la era de fusión de imágenes por resonancia magnética cognitiva/ultrasonido en la detección del cáncer. Acta Médica Peruana. 2022;39(2). https://doi.org/10.35663/amp.2022.392.2331.
Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. European Urology. 2015;68(1): 139–146. https://doi.org/10.1016/j.eururo.2014.08.010.
Lepor A, Catalona WJ, Loeb S. The Prostate Health Index. Urologic Clinics of North America. 2016;43(1): 1–6. https://doi.org/10.1016/j.ucl.2015.08.001.
Yáñez-Castillo YM, Melgarejo-Segura MT, Funes-Padilla C, Folgueral-Corral ME, García-Larios JV, Arrabal-Polo MA, et al. Prostate health index (PHI) as an accurate prostate cancer predictor. Journal of Cancer Research and Clinical Oncology. 2023;149(11): 9329–9335. https://doi.org/10.1007/s00432-023-04860-6.
Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy: PHI vs. PCA-3 to Detect Overall and Significant Prostate Cancer. The Prostate. 2015;75(1): 103–111. https://doi.org/10.1002/pros.22898.
Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cellular Oncology. 2016;39(2): 97–106. https://doi.org/10.1007/s13402-016-0268-6.
Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Therapeutic Advances in Urology. 2022;14: 175628722211039. https://doi.org/10.1177/17562872221103988.
Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, et al. Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature. Korean Journal of Urology. 2014;55(7): 436. https://doi.org/10.4111/kju.2014.55.7.436.
De La Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. Journal of Urology. 2015;194(1): 65–72. https://doi.org/10.1016/j.juro.2015.01.091.
Chiu ST, Cheng YT, Pu YS, Lu YC, Hong JH, Chung SD, et al. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection. Frontiers in Oncology. 2021;11: 772182. https://doi.org/10.3389/fonc.2021.772182.
Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study. Journal of Urology. 2010;183(4): 1355–1359. https://doi.org/10.1016/j.juro.2009.12.056.
Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter Evaluation of [−2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer. Clinical Chemistry. 2013;59(1): 306–314. https://doi.org/10.1373/clinchem.2012.195784.
Loeb S, Sokoll LJ, Broyles DL, Bangma CH, Van Schaik RHN, Klee GG, et al. Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. Journal of Urology. 2013;189(5): 1702–1706. https://doi.org/10.1016/j.juro.2012.11.149.
Park H, Lee SW, Song G, Kang TW, Jung JH, Chung HC, et al. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. Journal of Korean Medical Science. 2018;33(11): e94. https://doi.org/10.3346/jkms.2018.33.e94.
Lazzeri M, Haese A, Abrate A, De La Taille A, Redorta JP, McNicholas T, et al. Clinical performance of serum prostate‐specific antigen isoform [‐2] PROPSA ( P2PSA ) and its derivatives, % P2PSA and the prostate health index ( PHI ), in men with a family history of prostate cancer: results from a multicentre E uropean study, the PROMETHEUS project. BJU International. 2013;112(3): 313–321. https://doi.org/10.1111/bju.12217.
Filella X, Giménez N. Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2013;51(4): 729–739. https://doi.org/10.1515/cclm-2012-0410.
Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2022;60(8): 1261–1277. https://doi.org/10.1515/cclm-2022-0354.
Lopes Vendrami C, McCarthy RJ, Chatterjee A, Casalino D, Schaeffer EM, Catalona WJ, et al. The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. Urology. 2019;129: 153–159. https://doi.org/10.1016/j.urology.2019.03.018.
